Notably, the first-in-human phase 1 AUGMENT101 study of the menin-KMT2A inhibitor SNDX-5613 as monotherapy showed promising results in patients with relapsed/refractory AML carrying KMT2A rearrangements or NPM1 mutations. This evidence concerns the gene NPM1 and acute myeloid leukemia.